HER2 Expression and Treatment in Early Triple-Negative Breast Cancer
Author Information
Author(s): Muacevic Alexander, Adler John R, Tanaka Namiko, Imanishi Seiichi, Takeuchi Chisato, Goto Takayoshi, Kittaka Nobuyoshi
Primary Institution: Osaka Rosai Hospital
Hypothesis
This study aimed to evaluate the relationship among HER2 expression level, pathological complete response rate of neoadjuvant chemotherapy, and prognosis in early-stage triple-negative breast cancer.
Conclusion
HER2 expression did not correlate with the pCR rate of neoadjuvant chemotherapy but did correlate with distant disease-free survival and overall survival.
Supporting Evidence
- The pCR rates were 38.9%, 8.3%, and 44.4% for HER2 (0), HER2 (1+), and HER2 (2+, FISH; negative), respectively.
- Patients with HER2 (0) status are considered to have a poor prognosis and should be more aggressively considered for perioperative chemotherapy.
- HER2 expression was significantly decreased from before to after neoadjuvant chemotherapy (p = 0.001).
Takeaway
This study looked at how a protein called HER2 affects treatment outcomes in a type of breast cancer. It found that having low HER2 levels means a worse outlook for patients.
Methodology
This retrospective study analyzed the relationship among HER2 expression level, pCR rate, clinicopathological factors, and prognosis in 39 patients diagnosed with TNBC who underwent surgery after neoadjuvant chemotherapy.
Limitations
The study was conducted retrospectively with a limited number of samples.
Participant Demographics
Patients' age ranged from 33 to 86 years, with a median age of 57.
Statistical Information
P-Value
p = 0.032
Confidence Interval
95% CI = 0.037-0.813
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website